New Oral SERD Elacestrant -- for Which Breast Cancer Patients? New Oral SERD Elacestrant -- for Which Breast Cancer Patients?

New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news